Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus CEFZIL.
CEFUROXIME SODIUM vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic